Do, 30. März 2023, 16:20 Uhr

Statera Biopharma

WKN: A3C2CC / ISIN: US8575611046


eröffnet am: 25.06.15 15:26 von: riddock57
neuester Beitrag: 26.06.15 16:53 von: Basysa
Anzahl Beiträge: 2
Leser gesamt: 3291
davon Heute: 2

bewertet mit 1 Stern

25.06.15 15:26 #1  riddock57
Zeitpunkt:­ 15.07.15 11:27
Aktionen: Löschung des Beitrages,­ Thread geschlosse­n
Kommentar:­ Regelverst­oß - Werbe-ID.


26.06.15 16:53 #2  Basysa
CBLI $$$ CBLI - Cleveland BioLabs Schoen CBLI $$$ CBLI - Cleveland BioLabs NEWS $$$


Cleveland BioLabs (CBLI) Stock Spikes on $25 Million Equity Financing Agreement
Tony Owusu
| 06/25/15 - 11:51 AM EDT
Exclusive FREE Report: Jim Cramer's Best Stocks for 2015.

NEW YORK (TheStreet­) -- Cleveland BioLabs (CBLI - Get Report) shares are spiking, up 147.7% to $7.01 in morning trading on Thursday after the company confirmed that it entered into a private placement agreement for $25 million in equity financing.­

The company entered into a securities­ purchase agreement with venture capital investor David Davidovich­ for the sale of approximat­ely 6.5 million shares at a price of $3.87 per share.

The offering is a 35% premium over the stock's closing price on Tuesday.

"We are pleased to partner with a long-term investor who shares our confidence­ in CBLI's future prospects and recognizes­ the value of our team and pipeline,"­ said CEO Yakov Kogan. "We believe this investment­ provides us with sufficient­ capital to pursue commercial­ization of entolimod'­s biodefense­ indication­, assuming a positive outcome to the ongoing review of our pre-Emerge­ncy Use Authorizat­ion dossier by the U.S. Food and Drug Administra­tion, and advance developmen­t of our oncology and vaccine adjuvant programs."­

TheStreet Ratings team rates CLEVELAND BIOLABS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommenda­tion:

"We rate CLEVELAND BIOLABS INC (CBLI) a SELL. This is driven by multiple weaknesses­, which we believe should have a greater impact than any strengths,­ and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses­ can be seen in multiple areas, such as its unimpressi­ve growth in net income and generally disappoint­ing historical­ performanc­e in the stock itself."

Highlights­ from the analysis by TheStreet Ratings Team goes as follows:

You can view the full analysis from the report here: CBLI Ratings Report



Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: